# reload+after+2024-01-23 00:45:15.950653
address1§102 Woodmont Boulevard
address2§Suite 610
city§Nashville
state§TN
zip§37205
country§United States
phone§615 733 4730
website§https://www.harrow.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
fullTimeEmployees§217
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Mark L. Baum J.D.', 'age': 51, 'title': 'CEO & Chairman of the Board', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 1195141, 'exercisedValue': 0, 'unexercisedValue': 12564608}, {'maxAge': 1, 'name': 'Mr. Andrew R. Boll C.F.A., C.M.A.', 'age': 41, 'title': 'CFO & Corporate Secretary', 'yearBorn': 1982, 'fiscalYear': 2022, 'totalPay': 764386, 'exercisedValue': 0, 'unexercisedValue': 3642605}, {'maxAge': 1, 'name': 'Mr. John P. Saharek MBA', 'age': 63, 'title': 'Chief Commercial Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 656887, 'exercisedValue': 0, 'unexercisedValue': 3418270}, {'maxAge': 1, 'name': 'Dr. Dennis E Saadeh Pharm.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jamie  Webb', 'title': 'Director of Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kim  Barratt', 'title': 'Chief of Staff', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark A. Mannebach Ph.D., R.Ph.', 'title': 'Head of Regulatory Affairs & Pharmacovigilance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§8
compensationRisk§7
shareHolderRightsRisk§3
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.441
priceToSalesTrailing12Months§3.2420974
currency§USD
dateShortInterest§1702598400
forwardEps§0.16
pegRatio§-1.38
exchange§NGM
quoteType§EQUITY
shortName§Harrow, Inc.
longName§Harrow, Inc.
firstTradeDateEpochUtc§1190986200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2d3d154a-7423-3544-9b38-aa85176d4703
gmtOffSetMilliseconds§-18000000
targetHighPrice§34.4
targetLowPrice§20.0
targetMeanPrice§28.13
targetMedianPrice§30.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§4.871
grossMargins§0.69778
ebitdaMargins§0.11043
trailingPegRatio§None
